Newtown, Pennsylvania | February 19, 2026 — Traws Pharma announced completion of its clinical analysis evaluating ratutrelvir, an investigational oral antiviral, in both PAXLOVID®-eligible and ineligible COVID-19 patients, alongside development updates for tivoxavir marboxil as a prophylactic therapy for seasonal influenza. Findings from the Phase 2 study demonstrated a differentiated safety and tolerability profile, reinforcing ratutrelvir’s potential as an alternative treatment option for patients unable to receive ritonavir-boosted regimens.The company also reported progress advancing tivoxavir marboxil toward human prophylaxis studies targeting broad influenza protection.
Science Significance
Ratutrelvir is a novel oral Mpro/3CL protease inhibitor designed to treat SARS-CoV-2 infection without requiring ritonavir co-administration. Clinical analysis from the 90-patient open-label Phase 2 study showed fewer treatment-related adverse events and no viral rebound events, while maintaining comparable time to sustained symptom resolution versus PAXLOVID®.Importantly, therapeutic benefit was also observed in patients ineligible for ritonavir-boosted therapy due to contraindications or drug–drug interactions. This population represents a clinically underserved group lacking optimal antiviral options. Parallel scientific advancement was reported for tivoxavir marboxil, a CAP-dependent endonuclease inhibitor, where preclinical modeling suggests once-monthly prophylactic protection against seasonal influenza and pandemic variants.
Regulatory Significance
Completion of the ratutrelvir clinical analysis represents a key value inflection point for Traws Pharma’s antiviral pipeline. By targeting both COVID-19 treatment and influenza prophylaxis markets, the company is positioning itself within two multi-billion-dollar infectious disease segments.The dual-asset strategy enhances partnership and stockpiling opportunities, particularly with global health agencies focused on respiratory viral threats. Advancement of ritonavir-independent antivirals may also create competitive differentiation in future pandemic response frameworks.
Business Significance
Advertisement
For patients, ratutrelvir’s tolerability and lack of viral rebound could address critical treatment gaps. Individuals unable to receive ritonavir-boosted therapy—often due to comorbidities or medication interactions—represent a high-risk population for severe COVID-19 outcomes.Availability of an effective alternative antiviral could expand therapeutic access and reduce hospitalization risks. Meanwhile, tivoxavir marboxil’s potential once-monthly prophylactic protection may offer a transformative prevention strategy for vulnerable populations, including the elderly and immunocompromised.
Patients’ Significance
For patients, ratutrelvir’s tolerability and lack of viral rebound could address critical treatment gaps. Individuals unable to receive ritonavir-boosted therapy—often due to comorbidities or medication interactions—represent a high-risk population for severe COVID-19 outcomes.Availability of an effective alternative antiviral could expand therapeutic access and reduce hospitalization risks. Meanwhile, tivoxavir marboxil’s potential once-monthly prophylactic protection may offer a transformative prevention strategy for vulnerable populations, including the elderly and immunocompromised.
Policy Significance
The advancement of broad-spectrum antivirals aligns with global policy priorities emphasizing pandemic preparedness and respiratory virus mitigation. Development of both treatment and prophylactic agents supports strategic stockpiling initiatives, public health vaccination complements, and outbreak response frameworks. Regulatory collaboration across jurisdictions highlights the importance of harmonized clinical development pathways for antiviral countermeasures.
Traws Pharma’s latest clinical and preclinical updates underscore growing momentum in next-generation antiviral innovation. With ratutrelvir demonstrating differentiated clinical performance and tivoxavir marboxil advancing toward prophylactic validation, the company is expanding therapeutic and preventive options across major respiratory viral diseases. Continued regulatory engagement and clinical study execution will determine the speed at which these investigational agents may contribute to future infectious disease preparedness and patient care strategies.
Source: Traws Pharma press release
